Paulina Hill is a Principal at Polaris Partners. Paulina joined Polaris in 2011 and focuses on investments in healthcare.
Paulina serves on the boards of Arsenal Medical, Faraday Pharmaceuticals and KinDex Pharmaceuticals and is an observer on the boards of MicroCHIPS and 480 Biomedical. Paulina also works closely with Arsia Therapeutics, an early-stage Bob Langer-founded startup which she was actively involved in spinning out of MIT.
Paulina serves on the board of The Capital Network, a non-profit that provides fundraising education to startup entrepreneurs and is part of the Lead Mentor team for Canadian Entrepreneurs in New England.
Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at the Massachusetts Institute of Technology. In the laboratory of Bob Langer, Paulina worked on developing novel biomaterial scaffolds and drug delivery systems for neural applications. Paulina is the founding president of the MIT Postdoctoral Association, and served on the MIT Intellectual Property Presidential Committee.
Paulina completed her PhD in Molecular Medicine with a Tissue Engineering focus at Wake Forest University School of Medicine. Her graduate school work resulted in over 40 published abstracts, awards and peer reviewed manuscripts. Her research contributed to numerous patents and the formation of the startup KeraNetics to commercialize the platform technology.
Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. She attended East Carolina on an athletic scholarship where she was captain of the women’s tennis team.
MEDIA ABOUT PAULINA HILL